CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 6, 2008--Curis, Inc. (NASDAQ: CRIS), a drug development company focused on developing proprietary targeted medicines primarily for cancer treatment, today announced that the Company will be presenting at the BIO CEO & Investor Conference on Wednesday, February 13th, at the Waldorf-Astoria Hotel in New York City.
Daniel Passeri, Curis' President and Chief Executive Officer, will provide an overview of the status of Curis' business and collaborations at 2:00 p.m. Eastern. There will also be a corresponding webcast of the presentation, which can be accessed by visiting: www.corporate-ir.net/ireye/conflobby.zhtml?ticker=CRIS&item_id=1752316
The presentation will be archived shortly after the live event and available for 30 days following the conference. The presentation will also be available on the Investor Relations section of Curis' website at www.curis.com.
About Curis, Inc.
Curis is a drug development company that is committed to leveraging its innovative signaling pathway drug technologies in seeking to create new medicines, primarily for cancer. In expanding its drug development efforts in the field of cancer through its Targeted Cancer Drug Development Platform, the Company is building upon its experiences in targeting signaling pathways in the areas of cancer, neurological disease and cardiovascular disease. For more information, visit www.curis.com.
CONTACT: Curis, Inc.
Michael P. Gray, 617-503-6632
Chief Financial Officer and Chief Operating Officer
mgray@curis.com
SOURCE: Curis, Inc.